骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Catalyst制药宣布开展Firdapse治疗MuSK抗体阳性重症肌无力的IIb期临床试验

2019-01-06 MedSci MedSci原创

MuSK抗体阳性重症肌无力CatalystFirdapse
关注

Catalyst是一家生物制药公司，专注于为患有罕见的慢性神经疾病的患者开发和商业化创新疗法，Catalyst近日公布了Firdapse（磷酸氨苄西林）治疗MuSK抗体阳性重症肌无力（MuSK-MG）的IIb期临床试验（MSK-001）的最新结果。

Catalyst是一家生物制药公司，专注于为患有罕见的慢性神经疾病的患者开发和商业化创新疗法，Catalyst近日公布了Firdapse（磷酸氨苄西林）治疗MuSK抗体阳性重症肌无力（MuSK-MG）的IIb期临床试验（MSK-001）的最新结果。

MSK-001试验是一项随机、双盲、安慰剂对照、双交叉设计的临床试验，结果显示，磷酸氨苄西林达到了主要终点（QMG评分：p = 0.0003和MG日常生活概况评分：p = 0.0006）以及次要终点。该研究提供的证据表明磷酸氨苄西林在治疗MuSK-MG患者时是安全有效的。

重症肌无力是长期的神经肌肉疾病，会造成不同程度的肌肉无力。最常影响眼部、脸部及吞咽相关的肌肉。会造成复视、眼睑下垂、说话困难及行走困难等症状。重症肌无力可能会突然发生。患者多半有胸腺过大或是胸腺瘤的情形。如果重症肌无力 (MG) 患者血清肌肉特异性激酶 (MuSK) 抗体呈阳性则其症状可能更为严重，达到缓解的目标可能更难。


原始出处：

http://www.firstwordpharma.com/node/1615906?tsid=4#axzz5bnF206kJ

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-13 wgsun

    #MuSK抗体阳性重症肌无力#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-11-29 bioon3

    #Ib期#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-26 41514487@qq.com

    #抗体阳性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-16 jyzxjiangqin

    重症肌无力的治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-08 zhouqu_8

    #肌无力#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-08 bbjsj_1981

    #ATA#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1715741, encodeId=9ca81e15741a3, content=<a href='/topic/show?id=ce4912380bb' target=_blank style='color:#2F92EE;'>#MuSK抗体阳性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12380, encryptionId=ce4912380bb, topicName=MuSK抗体阳性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=563732008260, createdName=wgsun, createdTime=Sun Jan 13 23:15:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940330, encodeId=2e4b19403306d, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Nov 29 21:15:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948107, encodeId=5562194810ec6, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Jan 26 12:15:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358348, encodeId=6ca9358348bd, content=重症肌无力的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jan 16 15:51:24 CST 2019, time=2019-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436661, encodeId=2b2714366616a, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466073, encodeId=c1ed14660e360, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482826, encodeId=6d8814828264a, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jan 08 12:15:00 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-08 一叶知秋

    #APS#

    0